Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.

Carlos King-Ho Wong Kristy Tsz Kwan Lau Eric Ho Man Tang Chi Ho LeeCarmen Yu Yan LeeYu Cho WooIvan Chi Ho Au Kathryn Choon Beng Tan David Tak Wai Lui

Published in: Cardiovascular diabetology (2022)

Our real-world data suggested that SGLT2i-associated cardiovascular benefits were not attenuated by metformin use. Further studies will delineate the role of erythrocytosis as a surrogate marker of SGLT2i-associated cardiovascular benefit in reducing HHF.

Keyphrases

type diabetes
cardiovascular disease
electronic health record
insulin resistance
metabolic syndrome
adipose tissue
data analysis